|
1
|
Goel A and Aggarwal BB: Curcumin, the
golden spice from Indian saffron, is a chemosensitizer and
radiosensitizer for tumors and chemoprotector and radioprotector
for normal organs. Nutr Cancer. 62:919–930. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Basnet P and Skalko-Basnet N: Curcumin: an
anti-inflammatory molecule from a curry spice on the path to cancer
treatment. Molecules. 16:4567–4598. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siziopikou KP, Ariga R, Proussaloglou KE,
et al: The challenging estrogen receptor-negative/progesterone
receptor-negative/HER-2-negative patient: a promising candidate for
epidermal growth factor receptor-targeted therapy? Breast J.
12:360–362. 2006. View Article : Google Scholar
|
|
4
|
De Ruijter TC, Veeck J, de Hoon JP, et al:
Characteristics of triple-negative breast cancer. J Cancer Res Clin
Oncol. 137:183–192. 2011.PubMed/NCBI
|
|
5
|
Thike AA, Cheok PY, Jara-Lazaro AR, et al:
Triple-negative breast cancer: clinicopathological characteristics
and relationship with basal-like breast cancer. Mod Pathol.
23:123–133. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tan DS, Marchió C, Jones RL, et al: Triple
negative breast cancer: molecular profiling and prognostic impact
in adjuvant anthracycline-treated patients. Breast Cancer Res
Treat. 111:27–44. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Eralp Y, Derin D, Ozluk Y, et al: MAPK
overexprssion is associated with anthracycline resistance and
increased risk for recurrence in patients with triple-negative
breast cancer. Ann Oncol. 19:669–674. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wilken R, Veena MS, Wang MB and Srivatsan
ES: Curcumin: a review of anti-cancer properties and therapeutic
activity in head and neck squamous cell carcinoma. Mol Cancer.
10:12–31. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reuter S, Eifes S, Dicato M, et al:
Modulation of anti-apoptotic and survival pathways by curcumin as a
strategy to induce apoptosis in cancer cells. Biochem Pharmacol.
76:1340–1351. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kunnumakkara AB, Anand P and Aggarwal BB:
Curcumin inhibits proliferation, invasion, angiogenesis and
metastasis of different cancers through interaction with multiple
cell signaling proteins. Cancer Lett. 269:199–225. 2008. View Article : Google Scholar
|
|
11
|
Rowe DL, Ozbay T, O’Regan RM and Nahta R:
Modulation of the BRCA1 protein and induction of apoptosis in
triple negative breast cancer cell lines by the polyphenolic
compound curcumin. Breast Cancer (Auckland). 3:61–75.
2009.PubMed/NCBI
|
|
12
|
Oiso S, Ikeda R, Nakamura K, et al:
Involvement of NF-κB activation in the cisplatin resistance of
human epidermoid carcinoma KCP-4 cells. Oncol Rep. 28:27–32.
2012.
|
|
13
|
Chiu TL and Su CC: Curcumin inhibits
proliferation and migration by increasing the Bax to Bcl-2 ratio
and decreasing NFκBp65 expression in breast cancer MDA-MB-231
cells. Int J Mol Med. 23:469–475. 2009.PubMed/NCBI
|
|
14
|
Chakraborty G, Jain S, Kale S, et al:
Curcumin suppresses breast tumor angiogenesis by abrogating
osteopontin-induced VEGF expression. Mol Med Report. 1:641–646.
2008.PubMed/NCBI
|
|
15
|
Cui SX, Qu XJ, Xie YY, et al: Curcumin
inhibits telomerase activity in human cancer cell lines. Int J Mol
Med. 18:227–231. 2006.PubMed/NCBI
|
|
16
|
Mimeault M and Batra SK: Potential
applications of curcumin and its novel synthetic analogs and
nanotechnology-based formulations in cancer prevention and therapy.
Chin Med. 6:312011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hirose H, Ishii H, Mimori K, et al: Notch
pathway as candidate therapeutic target in Her2/Neu/ErbB2
receptor-negative breast tumors. Oncol Rep. 23:35–43.
2010.PubMed/NCBI
|
|
18
|
Lee JY, Lee YM, Chang GC, et al: Curcumin
induces EGFR degradation in lung adenocarcinoma and modulates p38
activation in intestine: the versatile adjuvant for gefitinib
therapy. PLoS One. 6:e237562011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chadalapaka G, Jutooru I, Burghardt R and
Safe S: Drugs that target specificity proteins downregulate
epidermal growth factor receptor in bladder cancer cells. Mol
Cancer Res. 8:739–750. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Billar JA, Dueck AC, Stucky CC, et al:
Triple-negative breast cancers: unique clinical presentations and
outcomes. Ann Surg Oncol. 17(Suppl 3): 384–390. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sutton LM, Han JS, Molberg KH, et al:
Intratumoral expression level of epidermal growth factor receptor
and cytokeratin 5/6 is significantly associated with nodal and
distant metastases in patients with basal-like triple-negative
breast carcinoma. Am J Clin Pathol. 134:782–787. 2010. View Article : Google Scholar
|
|
22
|
Ueno NT and Zhang D: Targeting EGFR in
triple negative breast cancer. J Cancer. 2:324–328. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sánchez-Muñoz A, Gallego E, de Luque V, et
al: Lack of evidence for KRAS oncogenic mutations in
triple-negative breast cancer. BMC Cancer. 10:1362010.PubMed/NCBI
|
